Table 2.
Anti-psoriasis drugs and their medical genetics of targets.
| Target | Genetic Disease Pathogenesis a | Drug (Mode of Action) b | Current Drug Indication c |
|---|---|---|---|
| IL17-A | GOF | Secukinumab (inhibitor) | Ankylosing Spondylitis (AS); Psoriatic Arthritis; Severe Plaque psoriasis; Moderate Plaque psoriasis |
| IL17-A | GOF | Ixekizumab (inhibitor) | Severe Plaque psoriasis; Moderate Plaque psoriasis |
| NOS3 | GOF | Prednisone (inhibitor) | Allergic Rhinitis (AR); Conjunctivitis, Seasonal Allergic; Psoriasis; Prostate Cancer; Lymphoma; Hodgkins Disease; Tuberculosis |
| NOS3/ARID5B | GOF | Methotrexate (inhibitor) | Severe Psoriasis; Systemic Lupus Erythematosus (SLE); Cancer, Breast; Acute Lymphocytic Leukemia (ALL) |
| STAT3 | GOF | Acitretin (inhibitor) | Keratinization disorders; Severe Psoriasis |
| TNF | GOF | Infliximab (inhibitor) | Ankylosing Spondylitis (AS); Crohn's Disease (CD); Plaque Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis (RA); Ulcerative Colitis (UC) |
| TNF | GOF | Golimumab (inhibitor) | Ankylosing Spondylitis (AS); Rheumatoid Arthritis; Psoriatic Arthritis; Ulcerative Colitis |
| TNF/NOS3 | GOF | Apremilast (inhibitor) | Psoriatic arthritis aggravated; Severe Plaque psoriasis; Moderate Plaque psoriasis |
| TNF/TNFRSF1B | GOF | Etanercept (inhibitor) | Ankylosing Spondylitis (AS); Graft Versus Host Disease (GVHD); Hidradenitis Suppurativa (HS); Plaque Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis |
| VDR | GOF | Atocalcitol (inhibitor) | Psoriasis |
| VDR | GOF | Tisocalcitate (inhibitor) | Psoriasis |
| VDR | GOF | Tacalcitol (inhibitor) | Psoriasis |
a,b Derived from OUgene (http://www.csbio.sjtu.edu.cn); c Derived from TTD, DrugBank, and ClinicalTrials. GOF: gain of function.